Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE)

Trial Profile

Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 May 2014

At a glance

  • Drugs Regorafenib (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms REVERCE; REVERECE
  • Sponsors Bayer Yakuhin
  • Most Recent Events

    • 31 May 2014 The study protocol presented at 50th Annual Meeting of the American Society of Clinical Oncology.
    • 15 Nov 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 07 Nov 2013 Planned initiation date changed from 1 Oct 2013 to 15 Nov 2013 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top